Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for Robert J. Bagley´┐Ż
13.97
+0.17 (1.23%)
Real-time:   11:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.72 - 14.24
52 week 8.10 - 18.90
Open 14.00
Vol / Avg. 204,173.00/1.02M
Mkt cap 702.26M
P/E     -
Div/yield     -
EPS -0.39
Shares 50.27M
Beta 1.02
Inst. own 34%
Aug 4, 2015
Q2 2015 Rockwell Medical Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Rockwell Medical Inc Earnings Release - 4:00PM EDT - Add to calendar
May 21, 2015
Rockwell Medical Inc Annual Shareholders Meeting
May 13, 2015
Rockwell Medical Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 Rockwell Medical Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Rockwell Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.64% -39.36%
Operating margin -27.46% -32.40%
EBITD margin - -30.57%
Return on average assets -15.21% -31.75%
Return on average equity -21.74% -61.55%
Employees 283 -
CDP Score - -

Address

30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company's lead branded drug, Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell's generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Thomas E. Klema CPA, MBA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 50
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 62
Bio & Compensation  - Reuters